Clinical Trial Update: Bupropion for Depression in ESRD Patients on Hemodialysis [Phase 4]

View source ↗

Summary

Phase 4 study of bupropion for major depressive disorder in patients with end-stage renal disease on hemodialysis was terminated, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Major Depressive Disorder

Drugs mentioned

• bupropion (bupropion)

Snippet

Sponsor: University of Arkansas | Conditions: Major Depression, End Stage Renal Disease | Phase 4 | Status: TERMINATED | Results posted: 2018-07-17